Best Value Stock to Buy for October 23rd

Zacks
Zacksで開く
Best Value Stock to Buy for October 23rd

Here is the stock with buy rank and strong value characteristics for investors to consider today, October 23rd:  

Universal Insurance Holdings UVE: This vertically integrated insurance holding company, which is principally engaged in the property and casualty insurance business, carries a Zacks Rank #1 (Strong Buy), and has witnessed the Zacks Consensus Estimate for its current year earnings increasing 26.4% over the last 60 days.

UNIVERSAL INSURANCE HOLDINGS INC Price and Consensus

UNIVERSAL INSURANCE HOLDINGS INC Price and Consensus

UNIVERSAL INSURANCE HOLDINGS INC price-consensus-chart | UNIVERSAL INSURANCE HOLDINGS INC Quote

Universal Insurance has a price-to-earnings ratio (P/E) of 7.90 compared with 66.30 for the industry. The company possesses a Value Score of A.

UNIVERSAL INSURANCE HOLDINGS INC PE Ratio (TTM)

UNIVERSAL INSURANCE HOLDINGS INC PE Ratio (TTM)

UNIVERSAL INSURANCE HOLDINGS INC pe-ratio-ttm | UNIVERSAL INSURANCE HOLDINGS INC Quote

 

See the full list of top ranked stocks here.

 

Learn more about the Value score and how it is calculated here.

Zacks' Research Chief Names "Stock Most Likely to Double"

Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.

This innovative software-as-a-service firm upped its user base +22% year over year. That rate is increasing and margins are expanding as AI efficiencies take effect. Of course, all our elite picks aren't winners, but this one could far surpass earlier Zacks' Stocks Set to Double like D-Wave Quantum, which shot up +680.1%.

Free: See Our Top Stock And 4 Runners Up

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report


 
UNIVERSAL INSURANCE HOLDINGS INC (UVE): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research